Author

I. Bulut

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:CRISPR screen· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

H. Syed· 2 shared T. Bagci-Onder· 2 shared A. C. Aksu· 1 shared A. Cingoz· 1 shared A. Isiklar· 1 shared A. P. Cribbs· 1 shared B. Cevatemre· 1 shared B. Dedeoglu· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. Syed

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Exploiting Epigenetic Targets to Overcome Taxane Resistance in Prostate Cancer

B. Cevatemre, I. Bulut, B. Dedeoglu, A. Isiklar, H. Syed, O. Yedier Bayram, T. Bagci-Onder, C. Acilan Ayhan

This study identifies BRPF reader proteins and epigenetic regulators as targets to overcome taxane resistance in prostate cancer by reversing ABCB1-mediated efflux and restoring taxane susceptibility.

bioRxiv · Aug 10, 2023Cancer Biology

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology